Xarelto: first novel anticoagulant licensed for ACS

Bayer has launched a new 2.5mg strength of Xarelto (rivaroxaban) for the prevention of atherothrombotic events after acute coronary syndromes (ACS) in patients with elevated cardiac biomarkers.

Rivaroxaban is a selective direct factor Xa inhibitor. | SCIENCE PHOTO LIBRARY
Rivaroxaban is a selective direct factor Xa inhibitor. | SCIENCE PHOTO LIBRARY

In ACS patients, rivaroxaban is administered at a dose of 2.5mg twice daily in combination with aspirin 75—100mg daily, with or without clopidogrel 75mg daily.1

Efficacy

The safety and efficacy of rivaroxaban was evaluated in 15,526 patients with a recent ACS, defined as ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) or unstable angina.1

When added to standard therapy including low-dose aspirin, rivaroxaban 2.5mg twice daily significantly reduced the primary composite endpoint of death from cardiovascular causes, MI or stroke compared with placebo, with rates of 9.1% and 10.7%, respectively, over 24 months (HR 0.84, 95% CI 0.72—0.97, p=0.02).2

Rivaroxaban also significantly reduced the risk of death from cardiovascular causes (2.7%, vs 4.1% for placebo, p=0.002) and death from any cause (2.9%, vs 4.5% for placebo, p=0.002) over 24 months.2

Safety

Rivaroxaban increased the risk of major bleeding not associated with coronary-artery bypass grafting (1.8%, vs 0.6% with placebo; HR 3.46, 95% CI 2.08—5.77, p<0.001), as well as the rate of bleeding requiring medical attention and the rate of intracranial haemorrhage. However, there was no statistically significant difference in fatal bleeding.2

NICE decision pending

A technology appraisal assessing the clinical and cost effectiveness of rivaroxaban for secondary prevention in ACS is due to be published in March 2015.

References:

  1. Xarelto Summary of Product Characteristics, July 2014.
  2. Mega JL et al. N Engl J Med 2012; 366:9—19.

View Xarelto drug record

Further information: Bayer plc

Follow MIMS on Twitter


Read these next

Oral anticoagulant accepted for NHS use after acute coronary syndromes

Oral anticoagulant accepted for NHS use after acute coronary syndromes

Rivaroxaban (Xarelto) has been accepted by NICE for...

Eliquis approved for DVT and PE

Eliquis approved for DVT and PE

Eliquis (apixaban) is now licensed for the treatment...

Xarelto licensed to treat pulmonary embolism

Xarelto licensed to treat pulmonary embolism

Xarelto (rivaroxaban) can now be prescribed for the...

NICE approves rivaroxaban for DVT and recurrent VTE

NICE approves rivaroxaban for DVT and recurrent VTE

The direct factor Xa inhibitor rivaroxaban has been...

NICE recommends rivaroxaban for stroke prevention in AF

NICE recommends rivaroxaban for stroke prevention in AF

Rivaroxaban (Xarelto) has been approved by NICE for...

Xarelto: two new indications for oral anticoagulant

Xarelto: two new indications for oral anticoagulant

The direct oral factor Xa inhibitor, rivaroxaban (Xarelto),...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.